9360 Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices 

B. Need and Uses 

This clearance covers the information 

that contractors must submit to comply 

with the following Federal Acquisition 

Regulation (FAR) requirements: 

• FAR 52.248–1, Value Engineering; 

52.248–2, Value Engineering-ArchitectEngineer; and 52.248–3, Value 

Engineering-Construction. 

These clauses require contractors 

submitting Value Engineering Change 

Proposals (VECP’s) to the Government 

to provide such details as: (1) A 

description of the differences between 

the existing contract requirement and 

the proposed requirement, and the 

comparative advantages and 

disadvantages of each; (2) a list and 

analysis of contract requirements that 

must be changed if the VECP is 

accepted; (3) a detailed cost estimate 

showing anticipated reductions 

associated with the VECP; (4) a 

statement of the time a modification 

accepting the VECP must be issued to 

achieve maximum cost reduction, and 

the effect on contract completion time; 

and (5) identification of any previous 

submissions of the VECP; the agencies 

and contract numbers involved and 

previous Government actions, if known. 

The Government will use the 

collected information to evaluate the 

VECP and, if accepted, to arrange for an 

equitable sharing plan. 

C. Annual Burden 

Respondents: 109. 

Total Annual Responses: 218. 

Total Burden Hours: 3,270. 

Obtaining Copies: Requesters may 

obtain a copy of the information 

collection documents from the GSA 

Regulatory Secretariat Division by 

calling 202–501–4755 or emailing 

GSARegSec@gsa.gov. Please cite OMB 

Control No. 9000–0027, Value 

Engineering Requirements. 

Janet Fry, 

Director, Federal Acquisition Policy Division, 

Office of Governmentwide Acquisition Policy, 

Office of Acquisition Policy, Office of 

Governmentwide Policy. 

[FR Doc. 2022–03561 Filed 2–17–22; 8:45 am] 

BILLING CODE 6820–EP–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Request for Information: AHRQ’s 

Proposed Patient-Centered Outcomes 

Research Trust Fund Strategic 

Framework 

AGENCY: Agency for Healthcare Research 

and Quality, HHS. 

ACTION: Notice of request for 

information. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

input from the public on its proposed 

strategic framework for AHRQ’s PatientCentered Outcomes Research Trust 

Fund investments. 

DATES: Comments on this notice must be 

received by April 19, 2022. AHRQ will 

not respond individually to responders 

but will consider all comments 

submitted by the deadline. 

ADDRESSES: Please submit all responses 

via email to: PCORTF@ahrq.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Karin Rhodes, MD, Chief 

Implementation Officer, Email: 

PCORTF@ahrq.hhs.gov, Telephone: 

301–427–1364 or 240–463–0872. 

SUPPLEMENTARY INFORMATION: AHRQ is 

authorized under 42 U.S.C. 299b–37 to 

broadly disseminate patient-centered 

outcomes research (PCOR) findings, 

including incorporation of PCOR 

findings into health information 

technology focused on clinical decision 

support, and to train researchers in the 

methods used to conduct PCOR. PCOR 

compares the impact of two or more 

preventive, diagnostic, treatment, or 

healthcare delivery approaches on 

health outcomes, including those that 

are meaningful to patients. AHRQ’s 

work under 42 U.S.C. 299b–37 is funded 

by the Patient-Centered Outcomes 

Research Trust Fund (PCORTF), 26 

U.S.C. 9511, which was established in 

2010 and reauthorized in 2019. To learn 

more about the PCORTF, please visit: 

https://www.ahrq.gov/pcor/potential-ofthe-pcortf/index.html. 

In response to the reauthorization of 

the PCORTF, AHRQ has developed a 

proposed strategic framework to guide 

future planning and evaluation of 

AHRQ’s PCORTF investments (the 

strategic framework). The strategic 

framework is consistent with AHRQ’s 

broader goal of improving the quality, 

safety, equity, and value of healthcare 

delivery. 

The proposed strategic framework 

identifies five priorities for improving 

healthcare delivery that are aligned with 

AHRQ’s mission and that have the 

potential to improve outcomes that 

patients care about. These priorities are 

interrelated, and all contribute to 

achieving the proposed strategic 

framework’s overall vision of equitable 

whole-person care across the lifespan. 

The proposed strategic framework is 

consistent with AHRQ’s Congressional 

authorization for investments from the 

PCORTF and is aligned with national 

health priorities. 

The AHRQ PCORTF strategic 

framework includes a mission, vision, 

high-level priorities, desired outcomes, 

and cross-cutting strategies for 

advancing the desired outcomes. This 

framework is expected to describe and 

inform the portfolio of AHRQ PCORTF 

investments. AHRQ will use this broad 

framework to guide long-range planning 

and to guide the development of 

projects and investments. 

AHRQ PCORTF-funded projects will 

be connected to components and subcomponents of the strategic framework. 

Use of the strategic framework is 

intended to ensure that AHRQ’s 

investments are coherently connected 

and advance the overall vision of 

advancing equitable whole-person care 

across the lifespan. The final strategic 

framework will also provide a basis for 

creating an evaluation framework, 

measuring the success of individual 

projects, and identifying the overall 

impact of AHRQ’s PCORTF 

investments. 

AHRQ is seeking public comment on 

the proposed strategic framework for 

AHRQ’s PCORTF investments. 

BILLING CODE 4160–90–P 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices 9361 

BILLING CODE 4160–90–C 

AHRQ hopes to receive feedback from 

patients, healthcare professionals, 

community groups, employers, health 

services researchers, dissemination and 

implementation scientists, 

communications experts, 

representatives from health systems, 

public and private payers, and other 

stakeholders. 

The input received from this public 

comment period will be used in refining 

and finalizing the strategic framework. 

Based on the final strategic framework, 

AHRQ intends to develop an 

operational plan, which will include 

specific short- and long-term objectives 

and a formative and summative 

evaluation. The overall goal of AHRQ’s 

planning process is to identify 

investments consistent with its PCORTF 

authorization that will have the greatest 

positive impact on health and 

healthcare. 

AHRQ is requesting information from 

the public regarding the following broad 

questions: 

1. AHRQ would like overall reactions 

to the strategic framework; is there any 

aspect of the framework that: 

a. Does not promote the vision of 

advancing equitable whole-person care 

across the lifespan? 

b. Does not address major challenges 

faced by the U.S. healthcare system? 

c. Could be improved (and if so, 

how)? 

2. AHRQ would like input on our 

(non-ranked) high-level priority areas: 

a. Do our proposed high-level 

priorities miss any areas of critical 

importance? 

b. Are any of the high-level priorities 

more important than others? 

3. AHRQ would like input on how to 

target investments within high-priority 

areas. For example, should AHRQ focus 

on: 

a. Specific ages/stages or apply 

AHRQ’s investments equally across the 

lifespan? 

b. Transitions in care? 

4. AHRQ would also appreciate 

suggestions for applying the strategic 

framework. For example: 

a. How can AHRQ improve the 

dissemination of patient-centered 

outcomes research evidence to decisionmakers at the local, State, and Federal 

levels? 

b. What targeted investments could 

AHRQ make to sustain progress towards 

the strategic framework’s desired 

outcomes? 

c. What AHRQ PCORTF investments 

could help improve healthcare provider 

trust, well-being, and retention? 

5. How can AHRQ have the greatest 

impact and success at achieving the 

vision and mission of the strategic 

framework? 

a. What is the most effective way to 

ensure the sustainability of initiatives 

that seek to enhance the integration of 

patient-centered outcomes research 

findings into practice? 

b. What complementary partnerships 

and collaborations (both public and 

private) would increase the impact of 

AHRQ’s PCORTF investments? 

c. What will be the best way of 

measuring progress and the overall 

impact of AHRQ’s PCORTF 

investments? 

6. Is there anything else you would 

like to share regarding the strategic 

framework? 

AHRQ is interested in all of the 

questions listed above, but respondents 

are welcome to address as many or as 

few as they choose and to address 

additional areas of interest not listed. It 

is helpful to identify which question a 

particular answer is a response to. 


jspears on DSK121TN23PROD with NOTICES1EN18FE22.000</GPH>
9362 Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices 

This RFI is for planning purposes 

only and should not be construed as a 

policy, solicitation for applications, or 

as an obligation on the part of the 

Government to provide support for any 

ideas identified in response to it. AHRQ 

will use the information submitted in 

response to this RFI at its discretion and 

will not provide comments to any 

responder’s submission. However, 

responses to the RFI may be reflected in 

future solicitation(s) or policies. The 

information provided will be analyzed 

and may appear in reports. Respondents 

will not be identified in any published 

reports. Respondents are advised that 

the Government is under no obligation 

to acknowledge receipt of the 

information received or provide 

feedback to respondents with respect to 

any information submitted. No 

proprietary, classified, confidential, or 

sensitive information should be 

included in your response. The contents 

of all submissions will be made 

available to the public upon request. 

Materials submitted must be publicly 

available or able to be made public. 

Dated: February 15, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–03551 Filed 2–17–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

SIP22–004, Disability and Health Data 

Collaborative: Using Data to Promote the 

Health and Wellness of People with 

Disabilities. 

Date: May 3, 2022. 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107– 

B, Atlanta, Georgia 30341, Telephone: 

(770) 488–6511, Email: JRaman@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–03554 Filed 2–17–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—RFA–PS–22– 

001, Implementing Pre-Exposure 

Prophylaxis for HIV Prevention in 

Syringe Service Programs; RFA–PS– 

22–002, Implementation Research on 

Telehealth Strategies To Support 

Retention in Care and Treatment 

Among Antiretroviral Therapy (ART) 

Patients and Pre-Exposure Prophylaxis 

(PrEP) Clients and RFA–PS–22–004, 

Understanding HIV/STD Risk and 

Enhancing PrEP Implementation 

Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and 

Other Men Who Have Sex With Men in 

a Transformational Era; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP) RFA–PS– 

22–001, Implementing Pre-exposure 

Prophylaxis for HIV Prevention in 

Syringe Service Programs; RFA–PS–22– 

002, Implementation Research on 

Telehealth Strategies to support 

Retention in Care and Treatment among 

Antiretroviral Therapy (ART) Patients 

and Pre-exposure Prophylaxis (PrEP) 

Clients; and RFA–PS–22–004, 

Understanding HIV/STD Risk and 

Enhancing PrEP Implementation 

Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and 

Other Men Who Have Sex with Men in 

a Transformational Era. 

Date: March 30, 2022. 

Time: 10:00 a.m.–5:00 p.m. (EDT). 

Place: Teleconference. 

The meeting was published in the 

Federal Register on February 4, 2022, 

Volume 87, Number 24, page 6562– 

6563. 

The meeting is being amended to 

remove RFA–PS–22–002, 

Implementation Research on Telehealth 

Strategies to Support Retention in Care 

and Treatment among Antiretroviral 

Therapy (ART) Patients and Preexposure Prophylaxis (PrEP) Clients and 

should read as follows: 

RFA–PS–22–001, Implementing Preexposure Prophylaxis for HIV 

Prevention in Syringe Service Programs 

and RFA–PS–22–004, Understanding 

HIV/STD Risk and Enhancing PrEP 

Implementation Messaging in a Diverse 

Community-Based Sample of Gay, 

Bisexual, and Other Men Who Have Sex 

with Men in a Transformational Era. 

The meeting is closed to the public. 

For Further Information Contact: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, CDC, 1600 Clifton 

Road NE, Mailstop US8–1, Atlanta, 

Georgia 30329, Telephone: (404) 718– 

8833, Email: GAnderson@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–03555 Filed 2–17–22; 8:45 am] 

BILLING CODE 4163–18–P 


jspears on DSK121TN23PROD with NOTICES1